EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudieOpen Access · CC BY 4.0

Ciprofloxacin Versus Fosfomycin for Empirical Prophylaxis Before Transrectal Prostate Biopsy: Clinical, Microbiological, and Patient-Reported Outcomes from a Prospective Study

Edgaras Burzinskis iD, Ieva Janulaityte iD, Guoda Burzinskiene iD, Darijus Skaudickas, Albinas Naudziunas, Astra Vitkauskiene

Medical Sciences · 2026

DOI: 10.3390/medsci14010091 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Medical Sciences, 2026. Verfasst von Edgaras Burzinskis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania. Hauptthemen laut MEDLINE: Fosfomycin, Ciprofloxacin, Prostate, Antibiotic Prophylaxis. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Faculty of Medicine of the Lithuanian University of Health Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Transrectal ultrasound-guided prostate biopsy remains the gold standard in diagnosing prostate cancer, but is associated with infectious and non-infectious complications. Increasing fluoroquinolone resistance and regulatory restrictions have prompted evaluation of alternative prophylactic strategies, including fluoroquinolone-sparing agents and targeted prophylaxis. This study compared ciprofloxacin and fosfomycin as empirical prophylactic agents, focusing on microbiological concordance, clinical outcomes, and patient-reported outcomes.

Methods

In this prospective observational study, 265 men undergoing transrectal ultrasound-guided prostate biopsy received empirical antibiotic prophylaxis with either ciprofloxacin (n = 146) or fosfomycin trometamol (n = 119). Rectal swabs were obtained prior to biopsy, and antimicrobial susceptibility was analyzed post hoc. Infectious and non-infectious complications were recorded. Lower urinary tract symptoms (IPSS), erectile function (IIEF-5), and patient-reported quality of life were assessed before and after biopsy.

Results

Microbiological concordance between administered prophylaxis and rectal flora susceptibility was higher in the ciprofloxacin group than in the fosfomycin group (80.1% vs. 65.0%, p = 0.007), while resistance rates were similar (10.9% vs. 10.2%). Post-biopsy fever occurred in 5.3% of patients, and hospitalization was required in 3.1%, with no significant differences between prophylaxis groups. IPSS increased significantly after biopsy (p < 0.001), while IIEF-5 scores remained unchanged. Patients with microbiological concordance reported significantly better post-biopsy quality of life (p = 0.006).

Conclusions

Ciprofloxacin and fosfomycin showed similar safety profiles as empirical prophylaxis before transrectal prostate biopsy. Although ciprofloxacin achieved higher microbiological concordance, fosfomycin remains a viable alternative. The link between microbial concordance and improved patient-reported quality of life underscores the importance of targeted prophylaxis and supports antimicrobial stewardship in prostate cancer diagnostics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FosfomycinCiprofloxacinProstateAntibiotic ProphylaxisAnti-Bacterial AgentsProstatic NeoplasmsHumansMaleProspective StudiesAgedMiddle AgedPatient Reported Outcome MeasuresQuality of LifeBiopsy

Stichwörter der Autor:innen

antibiotic prophylaxisantimicrobial resistanceciprofloxacinfosfomycinprostate biopsyquality of lifetargeted prophylaxis

Substanzen

FosfomycinCiprofloxacinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
  • Department of Obstetrics and Gynecology, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
  • Department of Urology, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
  • Department of Internal Medicine, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.

ORCID-Profile: Edgaras Burzinskis, Ieva Janulaityte, Guoda Burzinskiene

Förderung

  • Faculty of Medicine of the Lithuanian University of Health Sciences

Zitieren

APA

Burzinskis, E., Janulaityte, I., Burzinskiene, G., Skaudickas, D., Naudziunas, A., & Vitkauskiene, A. (2026). Ciprofloxacin Versus Fosfomycin for Empirical Prophylaxis Before Transrectal Prostate Biopsy: Clinical, Microbiological, and Patient-Reported Outcomes from a Prospective Study. Medical Sciences. https://doi.org/10.3390/medsci14010091

Vancouver

Burzinskis E, Janulaityte I, Burzinskiene G, Skaudickas D, Naudziunas A, Vitkauskiene A. Ciprofloxacin Versus Fosfomycin for Empirical Prophylaxis Before Transrectal Prostate Biopsy: Clinical, Microbiological, and Patient-Reported Outcomes from a Prospective Study. Medical Sciences. 2026. doi:10.3390/medsci14010091

BibTeX
@article{Burzinskis2026,
  author = {Burzinskis, Edgaras and Janulaityte, Ieva and Burzinskiene, Guoda and Skaudickas, Darijus and Naudziunas, Albinas and Vitkauskiene, Astra},
  title = {Ciprofloxacin Versus Fosfomycin for Empirical Prophylaxis Before Transrectal Prostate Biopsy: Clinical, Microbiological, and Patient-Reported Outcomes from a Prospective Study},
  journal = {Medical Sciences},
  year = {2026},
  doi = {10.3390/medsci14010091}
}
Kostenlos starten →